Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Samsung Electronics Co. Ld Regulatory Filings 2021

Feb 16, 2021

10553_pos_2021-02-16_a5e00906-26b0-49b7-8de3-0a0df42d5f96.html

Regulatory Filings

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 2455P

Samsung Electronics Co. Ld

16 February 2021

Transaction with Affiliate Company

Samsung Electronics Co., Ltd. (KS005930, KS005935, SMSN, SMSD) on February 16, 2021

announced that its Board of Directors has authorized the following related-party transaction

with an affiliated company.

Trademark License Agreement

-     Grant trademark license to Samsung Bioepis

□ Major Transaction Terms

Transaction Item License fee for use of trademark
Transaction Date February 27, 2021
Transaction Period February 1, 2021 - January 31, 2024
Transaction Value KRW 7,505 million

(total transaction value: KRW 7,505 million)
Contract Type Negotiated contract
Other information - The transaction date is the date when the trade license agreement with

  Samsung Bioepis was made.

- Transaction period is the contract period.

- The transaction value is an estimate and may change according to

  Samsung Bioepis revenue.

* The license fee is set at 0.5% of Samsung Bioepis' revenue (excluding

  revenue or purchases not related to the use of trademark) and shall be paid

  every year during the transaction period.

Other Information:

ž Number of Independent Directors Present at the BOD Meeting: 6/6

ž Attendance of Audit Committee: Y

※ This disclosure is in accordance with the Korean Fair Trade Act, which mandates that a company must disclose

financial and real estate transactions in the event the value of such a transaction is greater or equal to KRW 5 billion

and the counterparty is a financial affiliate of the party required to make the disclosure.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCGPUUUPUPGUBQ